



HLS Therapeutics Inc.

News Release

HLS Therapeutics Reports Annual Meeting Results

6/7/2024

TORONTO, June 7, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 7, 2024.

A total of 21,098,254 Common Shares, or 66.32% of the total Common Shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows:

Name of Nominee	Votes Cast FOR	% of Vote Cast FOR	Votes WITHHELD	% of Votes WITHHELD
John Welborn	18,209,962	88.85	2,284,420	11.15
Craig Millian	19,959,739	97.39	534,643	2.61
John Hanna	19,135,935	93.37	1,358,447	6.63
Rodney Hill	19,959,554	97.39	534,828	2.61
Laura Brege	19,118,129	93.28	1,376,253	6.72
Norma Beauchamp	16,442,226	80.23	4,052,156	19.77
Kyle Dempsey	19,032,703	92.87	1,461,679	7.13
Christian Roy	19,135,933	93.37	1,358,449	6.63

HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the Company's auditors with 21,098,117 votes (100%) cast "for" and 137 votes (0%) withheld.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic

areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.